A randomized clinical trial to test the effectiveness of a multifaceted intervention to increase HPV vaccination rates

Impact of a multifaceted, targeted intervention on the human papillomavirus vaccination rate in Swiss Primary Care: a cluster randomized controlled trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN55473884

Enrollment

1980

Registered

2021-06-04

Start date

2021-09-01

Completion date

Unknown

Last updated

2025-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Human papillomavirus Infections and Infestations

Interventions

Study physicians will be randomized into two groups (control and intervention). A statistician not involved in the study performs the randomization. They will use stratified randomization. 1. GPs who

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The study patient population is equal to the target population of the vaccines of interest. GPs will provide vaccinations according to the current Swiss vaccination recommendations publicized by the Swiss Ministry of Health (Swiss vaccination schedule 2020)

Exclusion criteria

Exclusion criteria: Does not meet inclusion criteria

Design outcomes

Primary

Measure	Time frame
Overall number of HPVv given in the first 6 months, reported in a specific case report form (CRF) at month 6	—

Secondary

Measure	Time frame
Current secondary outcome measures as of 13/02/2023: 1. HPVv uptake (1st dose [with exception of baseline period and month 6] and overall vaccination doses) in the intervention group and control group, reported in a specific case report form (CRF) during the baseline period and at 3, 6, and 12 months 2. The change in HPVv uptake (overall vaccination doses) reported in a specific case report form (CRF) from baseline to defined time points (3, 6 and 12 months) between the intervention group and control group 3. The change in HPV and HPVv knowledge and attitudes (at GP level) measured using a questionnaire at baseline and month 6 4. Basic demographic data of HPV vaccinated patients (gender and age), provided by GPs in the CRF after 6 and 12 months 5. HPVv first vaccination or booster vaccination, request of patient or recommendation by GP (or both), and HPVv given alone or in combination with other vaccines, provided by GPs in the CRF after 6 and 12 months _____ Previous secondary outcome measures: 1. HPVv uptake (1st dose [with exception of baseline period and month 6] and overall vaccination doses) in the intervention group and control group, reported in a specific case report form (CRF) during the baseline period and at 2, 4, 6, and 12 months 2. The change in HPVv uptake (overall vaccination doses) reported in a specific case report form (CRF) from baseline to defined timepoints (2, 4, 6 and 12 months) between the intervention group and control group 3. The change in HPV and HPVv knowledge and attitudes (at GP level) measured using a questionnaire at baseline and month 6 4. Basic demographic data of HPV vaccinated patients (gender and age), provided by GPs in the CRF after 6 and 12 months 5. HPVv first vaccination or booster vaccination, request of patient or recommendation by GP (or both), and HPVv given alone or in combination with other vaccines, provided by GPs in the CRF after 6 and 12 months	—

Measure

Time frame

Current secondary outcome measures as of 13/02/2023: 1. HPVv uptake (1st dose [with exception of baseline period and month 6] and overall vaccination doses) in the intervention group and control group, reported in a specific case report form (CRF) during the baseline period and at 3, 6, and 12 months 2. The change in HPVv uptake (overall vaccination doses) reported in a specific case report form (CRF) from baseline to defined time points (3, 6 and 12 months) between the intervention group and control group 3. The change in HPV and HPVv knowledge and attitudes (at GP level) measured using a questionnaire at baseline and month 6 4. Basic demographic data of HPV vaccinated patients (gender and age), provided by GPs in the CRF after 6 and 12 months 5. HPVv first vaccination or booster vaccination, request of patient or recommendation by GP (or both), and HPVv given alone or in combination with other vaccines, provided by GPs in the CRF after 6 and 12 months _____ Previous secondary outcome measures: 1. HPVv uptake (1st dose [with exception of baseline period and month 6] and overall vaccination doses) in the intervention group and control group, reported in a specific case report form (CRF) during the baseline period and at 2, 4, 6, and 12 months 2. The change in HPVv uptake (overall vaccination doses) reported in a specific case report form (CRF) from baseline to defined timepoints (2, 4, 6 and 12 months) between the intervention group and control group 3. The change in HPV and HPVv knowledge and attitudes (at GP level) measured using a questionnaire at baseline and month 6 4. Basic demographic data of HPV vaccinated patients (gender and age), provided by GPs in the CRF after 6 and 12 months 5. HPVv first vaccination or booster vaccination, request of patient or recommendation by GP (or both), and HPVv given alone or in combination with other vaccines, provided by GPs in the CRF after 6 and 12 months

—

Countries

Switzerland

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026